Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary extracted from

  • Schroeder, P.E.; Davidson, J.N.; Hasinoff, B.B.
    Dihydroorotase catalyzes the ring opening of the hydrolysis intermediates of the cardioprotective drug dexrazoxane (ICRF-187) (2002), Drug Metab. Dispos., 30, 1431-1435.
    View publication on PubMed

Application

EC Number Application Comment Organism
3.5.2.3 medicine activation of the cardioprotective agent dexrazoxane by the enzyme in heart, mechanism Mesocricetus auratus

Inhibitors

EC Number Inhibitors Comment Organism Structure
3.5.2.3 5-aminoorotate 1 mM, 90% inhibition Mesocricetus auratus
3.5.2.3 Furosemide 1 mM, 80% inhibition Mesocricetus auratus
3.5.2.3 additional information not inhibitory: 4-chlorobenzenesulfonamide Mesocricetus auratus

KM Value [mM]

EC Number KM Value [mM] KM Value Maximum [mM] Substrate Comment Organism Structure
3.5.2.3 0.02
-
 (S)-dihydroorotate pH 7.4, 15Ā°C Mesocricetus auratus

Organism

EC Number Organism UniProt Comment Textmining
3.5.2.3 Mesocricetus auratus
-
-
-

Substrates and Products (Substrate)

EC Number Substrates Comment Substrates Organism Products Comment (Products) Rev. Reac.
3.5.2.3 (S)-dihydroorotate + H2O
-
 Mesocricetus auratus N-carbamoyl-L-aspartate
-
 ?
3.5.2.3 dexrazoxane + H2O i.e. ICRF187 or (+)-1,2-bis(3,5-dioxopiperazin-1-yl)propane, cardioprotective agent Mesocricetus auratus ADR-925 i.e. N,NĀ’-[(1S)-1-methyl-1,2-ethanediyl]bis[N-(2-amino-2-oxoethyl)glycine], biologically active form ?